{"nctId":"NCT00927472","briefTitle":"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","startDateStruct":{"date":"2009-08"},"conditions":["Pediculosis"],"count":254,"armGroups":[{"label":"Malathion Gel","type":"EXPERIMENTAL","interventionNames":["Drug: Malathion gel 0.5%"]},{"label":"Nix Creme Rinse","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Permethrin 1% rinse"]}],"interventions":[{"name":"Malathion gel 0.5%","otherNames":[]},{"name":"Permethrin 1% rinse","otherNames":["Nix Creme Rinse"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed active head lice infestation\n\nExclusion Criteria:\n\n* Allergy to pediculicides or hair care products\n* Scalp conditions other than head lice\n* Previous head lice treatment within the past 4 weeks\n* Current antibiotic treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment.","description":"Treatment Success was evaluated using the Efficacy Intention to Treat (eITT) (LOCF) Efficacy ITT (eITT) was considered definitive.\n\nThe primary efficacy variable was the proportion of index subjects who were considered a Treatment Success 14 days after their last treatment (Day 14 visit if only treated on Day 1, Day 21 visit if treated on Day 1 and Day 7).\n\nIndex subject: 95 from 254 randomized (the youngest subject in the household who met index case criteria( having nits and at least 3 live lice))","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.98","spread":"3.25"},{"groupId":"OG001","value":"62.50","spread":"4.95"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Were Considered Treatment Success 14 Days After Their First Treatment in the Efficacy ITT (LOCF))","description":"Treatment Success in the Efficacy ITT (LOCF)\n\nThe secondary efficacy variable was the proportion of index subjects who were lice-free 14 days after their first treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.95","spread":null},{"groupId":"OG001","value":"70.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Index Subjects Lice-free 2 Weeks After Their Last Treatment","description":"Treatment Success in the Efficacy Intention to Treat (eITT) (No LOCF)\n\nThe primary efficacy variable was the proportion of index subjects who were considered a Treatment Success 14 days after their last treatment (Day 14 visit if only treated on Day 1, Day 21 visit if treated on Day 1 and Day 7).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.72","spread":null},{"groupId":"OG001","value":"58.33","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Index Subjects Lice-free 14 Days After Their Last Treatment","description":"Treatment Success in the Per Protocol Population (PPP)\n\nThe PPP included all subjects who complied strictly with the protocol and had outcome data for all required visits. Superiority analysis in the PPP was considered to be supportive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.30","spread":null},{"groupId":"OG001","value":"71.70","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of All Randomized Subjects Who Were Treated and Returned for at Least One Post-treatment Visit.(LOCF)","description":"Treatment Success in the Modified Intention to Treat (Modified ITT) (LOCF)\n\nThe Modified ITT included all randomized subjects who were treated and returned for at least one post-treatment visit. Subjects with missing efficacy data were included first with LOCF and then with non-LOCF","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.74","spread":null},{"groupId":"OG001","value":"72.97","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of All Randomized Subjects Who Were Treated and Returned for at Least One Post-treatment Visit (Non-LOCF).","description":"Treatment Success in the Modified ITT (non-LOCF)\n\nThe Modified ITT included all randomized subjects who were treated and returned for at least one post-treatment visit.\n\nSubjects with missing efficacy data were included first with LOCF and then with non-LOCF","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.78","spread":null},{"groupId":"OG001","value":"68.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Were Considered Treatment Success 14 Days After Their First Treatment in the Efficacy ITT (Non LOCF))","description":"Treatment Success in the Efficacy ITT (non LOCF)\n\nThe secondary efficacy variable was the proportion of index subjects who were lice-free 14 days after their first treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.19","spread":null},{"groupId":"OG001","value":"65.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Were Considered Treatment Success 14 Days After Their First Treatment in the PPP","description":"Treatment Success in the PPP\n\nThe secondary efficacy variable was the proportion of index subjects who were lice-free 14 days after their first treatment.\n\nThe evaluations in the PPP was considered supportive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.38","spread":null},{"groupId":"OG001","value":"80.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Were Considered Treatment Success 14 Days After Their First Treatment in the Modified ITT (LOCF)","description":"Treatment Success in the Modified ITT (LOCF)\n\nThe secondary efficacy variable was the proportion of index subjects who were lice-free 14 days after their first treatment.\n\nThe evaluations in the Modified ITT was considered supportive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.91","spread":null},{"groupId":"OG001","value":"82.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Were Considered Treatment Success 14 Days After Their First Treatment in the Modified ITT (Non LOCF)","description":"Treatment Success in the Modified ITT (non LOCF)\n\nThe secondary efficacy variable was the proportion of index subjects who were lice-free 14 days after their first treatment.\n\nThe evaluations in the Modified ITT was considered supportive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.45","spread":null},{"groupId":"OG001","value":"76.40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":126},"commonTop":["Application site irritation","Scab","Eye irritation","Otitis media","Pyoderma"]}}}